A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients

This study is testing a new drug called SG301 in combination with two existing drugs — pomalidomide and dexamethasone — for patients with multiple myeloma (a type of bone marrow cancer) that has returned or stopped responding to previous treatments. Participants will be randomly assigned to either the new combination or a placebo combination. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed multiple myeloma with measurable disease - You have received at least one prior treatment that included lenalidomide and a proteasome inhibitor (bortezomib, carfilzomib, or ixazomib) - You are in good enough health to participate (ECOG 0–2) and expected to live at least 3 months **You may NOT be eligible if...** - You have not received prior treatment with lenalidomide and a proteasome inhibitor - You have severe organ problems (heart, liver, kidneys) - You have active infections or other serious illnesses - You have previously been treated with pomalidomide Talk to your doctor to see if this trial is right for you.